Quantum-Si Incorporated (Class A) (QSI) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, QSI scores 44 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." Across its five pillars, the Fundamental Cash Engine scores 7 of 20 (ROIC -35%; FCF yield 0%), indicating the weakest contribution to the composite. Whale 13F Flow scores 16 of 20 (institutional accumulation and options positioning), the strongest pillar and the main offset in the rating. Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), the lowest pillar overall. Macro Regime Fit scores 10 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 8 of 20 (Altman Z 4.27; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor evaluating the stock today, the rating's central message is that the company is not currently generating cash returns, and the rating treats this as the dominant risk. Upside drivers implied by the data are limited to the institutional-positioning pillar and the 1.74% price change in the current session; the valuation tradeoff is that price of 1.75 sits within a 52-week range of $0.69 - $2.18 while earnings-based valuation metrics are not available in source data. The Piotroski F-Score of 3/9 and insider pillar of 3/20 indicate weak fundamental momentum and limited insider conviction. These are analytical observations, not personalized financial advice.

Quantum-Si Incorporated (Class A) is listed on NASDAQ and classified under the Industrials sector, Industrial Machinery/Components industry, per the company profile. Per the SEC financials, reported revenue was $2.4M in FY 2025, $3.1M in FY 2024, and $1.1M in FY 2023. The source data does not describe the company's specific products, customers, or revenue model beyond the news summaries, which reference a protein-sequencing program and a kit under development. Per the recent news wire, the company has reported a 19-amino-acid detection milestone on its Proteus platform.

Per the market data, gross margin is 47.3%, while operating and net margins are each -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 4.27 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported cash declined from $49.2M in FY 2024 to $21.6M in FY 2025 while free cash flow remained negative in each reported period. The balance sheet posture, per the forensic pillar, is weak on fundamental-strength measures despite the Altman Z reading.

Per the recent news wire, several headlines reference QSI market action and a 19-amino-acid detection milestone on the Proteus platform, tagged as catalysts. A separate headline reports that Quantum-Si regained Nasdaq compliance after a bid price recovery, also tagged as a catalyst. Other items, including a TradingView estimates report, a StockInvest.us forecast, and a Stock Titan article on a protein-sequencing kit, are tagged as market-wire items. A Timothy Sykes item references a "biotech turnaround" narrative. Risk watch items include the negative operating and net income in each reported period and declining reported cash. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

• What are the company's specific products, customers, and revenue drivers beyond the news references to a sequencing platform and kit?
• What is the reason for the decline in reported cash from $49.2M to $21.6M, and what is the company's funding runway at the reported free-cash-flow burn rate?
• Why is the FY 2023 cash and debt position reported as N/A, and what are the company's debt obligations?
• What drove the reported 2025 revenue of $2.4M versus $3.1M in 2024, and what is the outlook for commercial adoption?
• What is the basis for the Whale 13F Flow pillar score of 16/20, given that holder data is recorded as NONE?